This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Covetrus Future Growth

Future criteria checks 0/6

Key information

n/a

Earnings growth rate

54.7%

EPS growth rate

Healthcare earnings growth	15.7%
Revenue growth rate	5.6%
Future return on equity	10.6%
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

Recent updates

Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line

Aug 04

Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders

Jun 02

Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price

May 02

Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?

Jan 07

We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

Oct 21

An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued

Sep 16

Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain

Dec 18

Covetrus, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 12

Covetrus Q3 2020 Earnings Preview

Nov 09

Earnings and Revenue Growth Forecasts

NasdaqGM:CVET - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	5,341	N/A	125	N/A	2
12/31/2023	5,065	N/A	92	N/A	4
12/31/2022	4,789	N/A	112	N/A	4
6/30/2022	4,649	-13	2	60	N/A
3/31/2022	4,621	-40	70	126	N/A
12/31/2021	4,575	-54	42	102	N/A
9/30/2021	4,575	-56	44	104	N/A
6/30/2021	4,539	-90	-60	2	N/A
3/31/2021	4,376	-13	10	72	N/A
12/31/2020	4,339	-26	-5	53	N/A
9/30/2020	4,225	-19	31	80	N/A
6/30/2020	4,117	-940	112	154	N/A
3/31/2020	4,100	-996	18	58	N/A
12/31/2019	3,976	-980	64	103	N/A
9/30/2019	3,871	-948	93	130	N/A
6/30/2019	3,776	27	83	113	N/A
3/31/2019	3,772	65	131	157	N/A
12/29/2018	3,778	101	136	158	N/A
9/30/2018	3,791	69	74	94	N/A
6/30/2018	3,776	74	103	127	N/A
3/31/2018	3,649	67	42	64	N/A
12/30/2017	3,580	64	87	108	N/A
12/31/2016	3,353	70	92	105	N/A
12/26/2015	2,978	60	N/A	96	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CVET's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if CVET's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CVET's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CVET's revenue (5.6% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: CVET's revenue (5.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CVET's Return on Equity is forecast to be low in 3 years time (10.6%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company has been acquired

Covetrus Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased to US$23.00

Price target decreased to US$21.40

Price target decreased to US$28.60

Price target decreased to US$31.33

Price target raised to US$29.00

Price target raised to US$23.50

Recent updates

Covetrus, Inc. Files Form 15

Covetrus, Inc.(NasdaqGS:CVET) dropped from NASDAQ Composite Index

Covetrus Announces the Appointment of Michelle Bonfilio as Chief People Officer

Insider exercised options and sold US$185k worth of stock

Covetrus Appoints Margie B. Pritchard as General Counsel and Corporate Secretary

President notifies of intention to sell stock

Covetrus, Inc. Announces Retirement of Matthew Foulston as Executive Vice President, Effective December 31, 2022

Saxena White P.A. Announces Settlement of Class Action on Behalf of Purchasers of Covetrus, Inc. Common Stock

Second quarter 2022 earnings: EPS misses analyst expectations

Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line

Covetrus, Inc. to Report Q2, 2022 Results on Aug 04, 2022

President exercised options and sold US$196k worth of stock

President notifies of intention to sell stock

Key Executive exercised options and sold US$162k worth of stock

Independent Director recently sold US$709k worth of stock

President notifies of intention to sell stock

Executive VP & Global CFO exercised options and sold US$259k worth of stock

Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders

Price target increased to US$23.00

Clayton, Dubilier & Rice, LLC and TPG Global, LLC offered to acquire remaining 75.8% stake in Covetrus, Inc. (NasdaqGS:CVET) $2.2 billion.

Price target decreased to US$21.40

First quarter 2022 earnings: EPS misses analyst expectations

Covetrus® Introduces Innovative Cloud-Based Practice Management Software for Veterinarians in the United Kingdom, EMEA and Asia Pacific

Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price

Covetrus, Inc. to Report Q1, 2022 Results on May 05, 2022

President exercised options and sold US$149k worth of stock

Covetrus, Inc., Annual General Meeting, May 11, 2022

High number of new directors

Full year 2021 earnings: EPS exceeds analyst expectations

Covetrus, Inc. to Report Q4, 2021 Results on Feb 24, 2022

CEO, President & Director exercised options and sold US$111k worth of stock

Chief Administrative Officer exercised options and sold US$121k worth of stock

Covetrus, Inc. Announces the Launch of Covetrus Pulse

Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?

CEO, President & Director notifies of intention to sell stock

Price target decreased to US$28.60

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.34 loss in 3Q 2020)

CEO, President & Director exercised options and sold US$193k worth of stock

We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

Chief Administrative Officer exercised options and sold US$229k worth of stock

An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued

VP, Chief Accounting Officer & Global Controller Laura Phillips has left the company

Director recently bought US$116k worth of stock

Price target decreased to US$31.33

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.41 profit in 2Q 2020)

Covetrus, Inc. (NasdaqGS:CVET) entered into a definitive agreement to acquire VCP.

CEO, President & Director notifies of intention to sell stock

Covetrus Enhances to Their Practice Management Software to Help Veterinary Clinics Compete Online and Deliver More Complete Healthcare

Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)

CEO, President & Director notifies of intention to sell stock

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.26 loss in 1Q 2020)

Covetrus, Inc. 2021 Q1 - Results - Earnings Call Presentation

Is Covetrus (NASDAQ:CVET) Using Too Much Debt?

Covetrus, Inc.: Well Positioned To Enjoy Market Crosscurrents

CEO, President & Director exercised options and sold US$277k worth of stock

CEO, President & Director notifies of intention to sell stock

Independent Director recently sold US$203k worth of stock

Covetrus, Inc. Announces the Addition of Stacey M.M. Shirra as Vice President of Global Talent Management

Insider exercised options and sold US$59k worth of stock

Full year 2020 earnings released: US$0.16 loss per share (vs US$9.52 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?

Covetrus Appoints Link Welborn as Chief Veterinary Officer

Covetrus, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Covetrus Appoints Deborah Sharkey as Chief Consumer Officer

New 90-day high: US$39.89

Chief Administrative Officer notifies of intention to sell stock

Covetrus, Inc.(NasdaqGS:CVET) dropped from Russell 1000 Growth-Defensive Index